Brief: Almirall Gets Approval For Acne Treatment Seysara In China
29/01/2026 07:04
Jan 29 (Reuters) - Almirall SA ALM.MC: ANNOUNCES THE APPROVAL OF SEYSARA® IN CHINA FOR THE TREATMENT OF MODERATE-TO-SEVERE ACNE SEYSARA EXPECTED TO BE AVAILABLE IN CHINA IN 2026 ENTERED INTO LICENCE AGREEMENT WITH SINOMUNE TO COMMERCIALISE AND DISTRIBUTE PRODUCT IN CHINA Source text Further company coverage: ALM.MC (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Almirall
See all newsBrief: Almirall Says Phase 3B Adlong Clinical Study Show Treatment Outcomes With Up To Five Years Of Lebrikizumab
Brief: Almirall And CrystalO To Discover, Develop Novel Small Molecules In Medical Dermatology
Almirall shares rise as lower costs beat EBITDA estimates
Brief: Almirall, Certest Biotec Sign Deal to Develop Rare Dermatology Treatments
Spanish stocks - Factors to watch on July 24